S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
NASDAQ:GNTA

Genenta Science (GNTA) Stock Price, News & Analysis

$4.19
-0.21 (-4.77%)
(As of 03/1/2024 ET)
Today's Range
$4.10
$4.22
50-Day Range
$3.14
$5.10
52-Week Range
$3.11
$7.08
Volume
2,557 shs
Average Volume
3,656 shs
Market Capitalization
$76.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Genenta Science MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Genenta Science in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.56) to ($0.93) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.30 out of 5 stars

Medical Sector

926th out of 951 stocks

Biological Products, Except Diagnostic Industry

147th out of 151 stocks


GNTA stock logo

About Genenta Science Stock (NASDAQ:GNTA)

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. The company was incorporated in 2014 and is headquartered in Milan, Italy.

GNTA Stock Price History

GNTA Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Genenta Science S.p.A. (GNTA)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Genenta Science S.p.A. ADR
Genenta to Present at Upcoming Investor Conferences
See More Headlines
Receive GNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genenta Science and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/02/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GNTA
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.80 per share

Miscellaneous

Free Float
12,936,000
Market Cap
$76.34 million
Optionable
Not Optionable
Beta
0.79
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Pierluigi Paracchi (Age 51)
    Vice Chairman of the Board, CEO & GM
  • Dr. Luigi Naldini M.D. (Age 65)
    Ph.D., Co-Founder & Chairman of the Executive Scientific Board
  • Dr. Bernard Rudolph Gentner M.D. (Age 49)
    Ph.D., Co-Founder & Member of the Executive Scientific Board
  • Mr. Richard B. Slansky (Age 66)
    Chief Financial Officer
  • Dr. Carlo Russo M.D. (Age 71)
    Chief Medical Officer & Head of Development
  • Dr. Stefania Mazzoleni Ph.D. (Age 42)
    Director of Program Development
  • Ms. Barbara Regonini
    Director of Finance














GNTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Genenta Science stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genenta Science in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GNTA shares.
View GNTA analyst ratings
or view top-rated stocks.

How have GNTA shares performed in 2024?

Genenta Science's stock was trading at $4.95 at the beginning of the year. Since then, GNTA shares have decreased by 15.4% and is now trading at $4.19.
View the best growth stocks for 2024 here
.

Are investors shorting Genenta Science?

Genenta Science saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 3,700 shares, an increase of 5.7% from the January 31st total of 3,500 shares. Based on an average daily trading volume, of 2,800 shares, the short-interest ratio is presently 1.3 days.
View Genenta Science's Short Interest
.

When is Genenta Science's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our GNTA earnings forecast
.

When did Genenta Science IPO?

(GNTA) raised $28 million in an IPO on Wednesday, December 15th 2021. The company issued 2,400,000 shares at a price of $10.50-$12.50 per share.

How do I buy shares of Genenta Science?

Shares of GNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GNTA) was last updated on 3/3/2024 by MarketBeat.com Staff